Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PBRM1 | Q86U86 | 1/20 | 0.35 |
| ▸ | BACE1 | P56817 | 7/20 | 0.32 |
| ▸ | APP | P05067 | 6/20 | 0.32 |
| ▸ | PIK3CD | O00329 | 1/20 | 0.30 |
| ▸ | PIK3CA | P42336 | 1/20 | 0.30 |
| ▸ | PIK3CB | P42338 | 1/20 | 0.30 |
| ▸ | PIK3CG | P48736 | 1/20 | 0.30 |
| ▸ | BCHE | P06276 | 1/20 | 0.30 |
| ▸ | AR | P10275 | 1/20 | 0.30 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL9931775 | 1.00 | PBRM1 (0.35) | PBRM1BACE1APPPIK3CDPIK3CA | |
| SCHEMBL9932206 | 0.91 | PBRM1 (0.34) | PBRM1BACE1APP | |
| SCHEMBL9932204 | 0.91 | PBRM1 (0.34) | PBRM1BACE1APP | |
| SCHEMBL9932454 | 0.85 | PBRM1 (0.40) | PBRM1BACE1APPBCHEAR | |
| SCHEMBL891447 | 0.85 | PBRM1 (0.40) | PBRM1BACE1APPBCHEAR | |
| SCHEMBL892643 | 0.85 | PBRM1 (0.40) | PBRM1BACE1APPBCHEAR | |
| SCHEMBL882871 | 0.85 | PBRM1 (0.40) | PBRM1BACE1APPBCHEAR | |
| SCHEMBL892637 | 0.79 | PBRM1 (0.39) | PBRM1BACE1APPBCHEAR | |
| SCHEMBL9882345 | 0.79 | PBRM1 (0.39) | PBRM1BACE1APPBCHEAR | |
| SCHEMBL9932579 | 0.77 | PBRM1 (0.40) | PBRM1AR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20120157448-A1 | COMPOUNDS FOR TREATING NEURODEGENERATIVE DISEASES | GENENTECH, INC. | 2012-06-21 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120157448-A1 | COMPOUNDS FOR TREATING NEURODEGENERATIVE DISEASES | BACE1, PSEN1, PSEN2 | PBRM1 3853/4885BACE1 1/4885APP 4/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.